MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

MDT

87.86

-1.21%↓

VEEV

221.66

-2.12%↓

A

109.71

-5.41%↓

HQY

82.88

-6.59%↓

PDCO

31.2

-0.22%↓

Search

Abbott Laboratories

Затворен

СекторЗдравеопазване

131.66 -0.32

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

131.22

Максимум

133.52

Ключови измерители

By Trading Economics

Приходи

7.6B

9.2B

Продажби

339M

11B

P/E

Средно за сектора

17.363

63.778

EPS

1.34

Дивидентна доходност

1.78

Марж на печалбата

84.099

Служители

114,000

EBITDA

82M

3B

Препоръки

By TipRanks

Препоръки

Силна покупка

12-месечна прогноза

+6.28% upside

Дивиденти

By Dow Jones

Дивидентна доходност

Средно за сектора

1.78%

2.39%

Следващи печалби

16.04.2025 г.

Следваща дата на дивидент

15.05.2025 г.

Следваща дата на екс-дивидент

15.04.2025 г.

Пазарни показатели

By TradingEconomics

Пазарна капитализация

7.8B

230B

Предишно отваряне

131.98

Предишно затваряне

131.66

Настроения в новините

By Acuity

27%

73%

81 / 386 Класиране в Healthcare

Техническа оценка

By Trading Central

Увереност

Strong Bullish Evidence

Abbott Laboratories Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

22.01.2025 г., 19:03 ч. UTC

Печалби

Correction to Abbott Labs 4Q Sales Just Miss Estimates Article

22.01.2025 г., 18:20 ч. UTC

Печалби

Abbott Labs 4Q Sales Just Miss Estimates; Shares Rise on 2025 Outlook -- Update

22.01.2025 г., 12:45 ч. UTC

Печалби

Abbott Labs 4Q Sales Underwhelm Amid Diminished Demand for Covid-19 Related Sales

1.11.2024 г., 14:15 ч. UTC

Значими двигатели на пазара

Reckitt, Abbott Shares Rise After Baby-Formula Lawsuit Win -- Update

1.11.2024 г., 10:10 ч. UTC

Значими двигатели на пазара

Reckitt Shares Surge After Baby Formula Lawsuit Win

31.10.2024 г., 23:57 ч. UTC

Горещи акции

Stocks to Watch: Intel, Amazon.com, Abbott Laboratories, MasTec

31.10.2024 г., 23:14 ч. UTC

Значими двигатели на пазара

Abbott Laboratories Shares Rise After Baby-Formula Verdict

16.10.2024 г., 12:03 ч. UTC

Печалби

Abbott Laboratories 3Q Sales Top Expectations

1.02.2025 г., 18:14 ч. UTC

Топ новини

Musk's X Adds Nestlé, Colgate, Shell, Other Brands to Ad-Boycott Suit -- WSJ

22.01.2025 г., 16:40 ч. UTC

Топ новини
Печалби

Abbott Laboratories Stock Turns Positive. What to Know From Its Earnings. -- Barrons.com

22.01.2025 г., 15:20 ч. UTC

Печалби

Abbott Laboratories Posts 'Middling' Quarter, But Diabetes Devices Shine -- IBD

22.01.2025 г., 15:08 ч. UTC

Печалби

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22.01.2025 г., 13:51 ч. UTC

Печалби

Abbott Laboratories Slides On Light Fourth-Quarter Sales, In-Line Profit -- IBD

22.01.2025 г., 13:39 ч. UTC

Топ новини
Печалби

Abbott Laboratories Stock Falls After Earnings as Sales Miss Estimates -- Barrons.com

22.01.2025 г., 12:02 ч. UTC

Печалби

Abbott Labs Sees 1Q Adj EPS $1.05-Adj EPS $1.09 >ABT

22.01.2025 г., 12:01 ч. UTC

Печалби

Abbott Labs Sees 2025 Adj EPS $5.05-Adj EPS $5.25 >ABT

22.01.2025 г., 12:01 ч. UTC

Печалби

Abbott Labs Sees 2025 Adjusted Operating Margin 23.5%-24% >ABT

22.01.2025 г., 12:00 ч. UTC

Печалби

Abbott Labs Sees 2025 Organic Sales Growth 7.5%-8.5% >ABT

22.01.2025 г., 12:00 ч. UTC

Печалби

Abbott Labs 4Q Net $9.23B >ABT

22.01.2025 г., 12:00 ч. UTC

Печалби

Abbott Labs 4Q Sales $10.97B >ABT

22.01.2025 г., 12:00 ч. UTC

Печалби

Abbott Labs 4Q Organic Sales Growth Up 8.8% >ABT

22.01.2025 г., 12:00 ч. UTC

Печалби

Abbott Labs 4Q EPS $5.27 >ABT

22.01.2025 г., 12:00 ч. UTC

Печалби

Abbott Labs 4Q Adj EPS $1.34 >ABT

22.01.2025 г., 09:54 ч. UTC

Горещи акции

Stocks to Watch Wednesday: Netflix, Oracle, Trump Media, Softbank -- WSJ

1.11.2024 г., 17:33 ч. UTC

Пазарно говорене

Abbott's Baby-Formula Lawsuit Win Could Decrease Liabilities -- Market Talk

16.10.2024 г., 14:21 ч. UTC

Топ новини
Печалби

Abbott Posts Solid Quarter. The Stock Is Rising. -- Barrons.com

16.10.2024 г., 12:25 ч. UTC

Печалби

Abbott Labs Beats Q3 Sales And Earnings Expectations, Raises Full-Year Outlook -- MarketWatch

16.10.2024 г., 12:02 ч. UTC

Топ новини
Печалби

Abbott Posts Solid Quarter. That Wasn't Enough to Lift Shares. -- Barrons.com

16.10.2024 г., 11:59 ч. UTC

Печалби

Abbott Earnings Edge Past Q3 Views, Led By Medical Devices -- IBD

16.10.2024 г., 11:37 ч. UTC

Печалби

Abbott Labs Sees 4Q Adj EPS $1.31-Adj EPS $1.37 >ABT

Сравнение с други в отрасъла

Ценова промяна

Abbott Laboratories Прогноза

Ценова цел

By TipRanks

6.28% нагоре

12-месечна прогноза

Среден 140.21 USD  6.28%

Висок 158 USD

Нисък 117 USD

Според 16 анализатори от Wall Street, предложили 12-месечна ценова цел за Abbott Laboratories през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

16 ratings

14

Купи

2

Задържане

0

Продай

Техническа оценка

By Trading Central

126.38 / 132.65Подкрепа & съпротива

Краткосрочен план

Strong Bullish Evidence

Средносрочен план

Strong Bullish Evidence

Дългосрочен план

Bullish Evidence

Настроение

By Acuity

81 / 386 Класиране в Здравеопазване

Настроения в новините

Бичи доказателства

Волатилност

Под средното

Обем новини (RCV)

Над средното

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Abbott Laboratories

Abbott Laboratories, together with its subsidiaries, discovers, develops, manufactures, and sells health care products worldwide. It operates in four segments: Established Pharmaceutical Products, Diagnostic Products, Nutritional Products, and Medical Devices. The company provides generic pharmaceuticals for the treatment of pancreatic exocrine insufficiency, irritable bowel syndrome or biliary spasm, intrahepatic cholestasis or depressive symptoms, gynecological disorder, hormone replacement therapy, dyslipidemia, hypertension, hypothyroidism, Ménière's disease and vestibular vertigo, pain, fever, inflammation, and migraine, as well as provides anti-infective clarithromycin, influenza vaccine, and products to regulate physiological rhythm of the colon. It also offers laboratory and transfusion medicine systems in the areas of immunoassay, clinical chemistry, hematology, and transfusion; molecular diagnostics polymerase chain reaction instrument systems that automate the extraction, purification, and preparation of DNA and RNA from patient samples, and detect and measure infectious agents; point of care systems; cartridges for testing blood gas, chemistry, electrolytes, coagulation, and immunoassay; rapid diagnostics lateral flow testing products; molecular point-of-care testing for HIV, SARS-CoV-2, influenza A and B, RSV, and strep A; cardiometabolic test systems; drug and alcohol test, and remote patient monitoring and consumer self-test systems; and informatics and automation solutions for laboratories. In addition, the company provides pediatric and adult nutritional products; rhythm management, electrophysiology, heart failure, vascular, and structural heart devices for the treatment of cardiovascular diseases; diabetes care products, such as glucose and blood glucose monitoring systems; and neuromodulation devices for the management of chronic pain and movement disorders. Abbott Laboratories was founded in 1888 and is based in North Chicago, Illinois.